<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04670237</url>
  </required_header>
  <id_info>
    <org_study_id>MC_Liberty677MTY_HU_2019</org_study_id>
    <nct_id>NCT04670237</nct_id>
  </id_info>
  <brief_title>Clinical Outcome After Implantation of Medicontur Liberty 677MTY, a Multifocal, Toric IOL</brief_title>
  <official_title>Clinical Outcome After Implantation of Medicontur Multifocal, Toric Intraocular Lens Liberty 677MTY: Rotational Stability, Visual Outcomes, Patients' Satisfaction, YAG Capsulotomy Rate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicontur Medical Engineering Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medicontur Medical Engineering Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate visual outcomes, patient satisfaction and YAG&#xD;
      capsulotomy rate after implantation of a multifocal toric lens- Liberty 677MTY - manufactured&#xD;
      by Medicontur Ltd. (Zsámbék, Hungary),&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate visual outcomes, glass independency, visual&#xD;
      disturbances (glares, halos), neuronal adaptation and patient satisfaction after implantation&#xD;
      of multifocal diffractive apodized toric intraocular lens- Liberty 677MTY -&#xD;
      diffractive-refractive apodized IOL based on EPS technology manufactured by Medicontur Ltd.&#xD;
      (Zsámbék, Hungary).&#xD;
&#xD;
      The tested IOL model, Liberty 677MTY, has an overall length of 13 mm, an optic diameter of&#xD;
      6.0 mm without haptics angulations but with posterior vaulting. The refractive index of the&#xD;
      optic material is 1.46 (at 23°C). The IOL is a single-piece-IOL, the optic and haptics are&#xD;
      made from a hydrophilic acrylic co-polymer with integrated - covalently bound UV absorbent.&#xD;
      The IOL is produced with yellow filter, covalently bound yellow chromophore. The toric&#xD;
      component of Liberty 677MTY IOL is located on the posterior surface of the lens optic. The&#xD;
      optic is marked with 2 marks. The marks are positioned exactly in middle between the two&#xD;
      loops of haptic at the angulation at the flat axis of toric equivalent. The Liberty 677MTY is&#xD;
      available with cylinder powers of 1.0 diopter (D) to 6.0 D. The IOL is designed with sharp&#xD;
      edge following 360º to prevent migration of the lens epithelial cells , thereby to prevent&#xD;
      PCO formation.&#xD;
&#xD;
      The trifocality of the lens is provided by the EPS technology recently developed by&#xD;
      Medicontur uses an elevated phase shift on the central diffractive part of the lens in order&#xD;
      to cause constructive interference between the 0th (far) and 1st diffractive (near) order,&#xD;
      thus creating a 3rd (intermediate) focal point.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rotational stability</measure>
    <time_frame>1 year</time_frame>
    <description>Rotational stability will be measured using slit lamp images of the implanted lens on day one, seven, month one, three and one year postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual outcome</measure>
    <time_frame>1 year</time_frame>
    <description>Monocular and binocular visual aquity will be measured at far, intermediate and near by standard ETDRS chart at month one, three and one year postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast sensitivity</measure>
    <time_frame>1 year</time_frame>
    <description>Contrast sensitivity will be assessed by using the CSV-1000 method in photopic and mesopic light condition three month and one year after implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>YAG capsulatomy</measure>
    <time_frame>1 year</time_frame>
    <description>The rate of YAG capsulatomy will be assessed during the one year follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>1 year</time_frame>
    <description>Patient satisfaction will be assessed by using the VFQ-25 questionnaire three month and one year postoperatively</description>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Cataract</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Liberty677MTY Multifocal Toric IOL</intervention_name>
    <description>multifocal, toric intraocular lens (IOL)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The enrolled subjects will be the patients with cataract and pre-existing regular corneal&#xD;
        astigmatism between 1.0 to 6.0 dpt. (Cylindric power of IOLs will range between 1.0 to 6.0&#xD;
        dpts). The patients will be indicated for cataract surgery and toric IOL implantation by&#xD;
        the clinical investigator. The study will be conducted according to the tenets of the&#xD;
        Declaration of Helsinki and patients will give informed consent after the nature and intent&#xD;
        of study will be fully explained to them.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  astigmatism less than 1 dpt&#xD;
&#xD;
          -  irregural astigmatism&#xD;
&#xD;
          -  diabetic retinopathy&#xD;
&#xD;
          -  iris neovascularisation&#xD;
&#xD;
          -  serious intraoperative complications&#xD;
&#xD;
          -  congenital eye abnormality&#xD;
&#xD;
          -  glaucoma&#xD;
&#xD;
          -  pseudoexfoliation syndrom&#xD;
&#xD;
          -  amblyopia&#xD;
&#xD;
          -  uveitis&#xD;
&#xD;
          -  long-term anti-inflammatory treatment&#xD;
&#xD;
          -  AMD (advanced AMD)&#xD;
&#xD;
          -  retinal detachment&#xD;
&#xD;
          -  prior ocular surgery in personal medical history&#xD;
&#xD;
          -  corneal diseases&#xD;
&#xD;
          -  severe retinal diseases (dystrophy, degeneration)&#xD;
&#xD;
          -  severe myopia (if required IOL power is lower than 10 D)&#xD;
&#xD;
          -  inadequate visualization of the fundus on preoperative examination&#xD;
&#xD;
          -  patients deemed by the clinical investigator because of any systemic disease.&#xD;
&#xD;
          -  eye trauma in medical history intraoperative exclusions:&#xD;
&#xD;
          -  tear in capsulorhexis&#xD;
&#xD;
          -  zonular dehiscence&#xD;
&#xD;
          -  posterior capsular rupture&#xD;
&#xD;
          -  vitreous loss and other unexpected surgical complication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>86 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Semmelweis University, Department of Ophthalmology</name>
      <address>
        <city>Budapest</city>
        <zip>H-1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 10, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

